NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
Clinical Trials
34 trialsNCT04467593 2025-08-05
MATTERS
ElmediX
Phase NA Completed
NCT01711671 2025-08-03
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Leap Therapeutics, Inc.
Phase 1 Completed
NCT03575351 2025-08-03
TRANSFORM
Celgene
Phase 3 Completed
NCT06504524 2025-06-27
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
Pfizer
Completed
NCT05801965 2025-05-25
A Digital Therapeutic Solution for Cancer Patients
Sidekick Health
Phase NA Completed
NCT06592222 2025-05-20
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
Pfizer
Completed
NCT05236257 2024-12-10
EPI VITRAKVI
Bayer
Completed
NCT05932290 2024-10-29
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma
Pfizer
Completed
NCT04982627 2024-07-03
BNICHAT
Center for Progressive Recovery, LLC
Phase NA Completed
NCT05565391 2024-05-21
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Pfizer
Completed
NCT00556374 2023-07-27
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Amgen
Phase 3 Completed
NCT03501173 2023-07-25
GURC
Janssen Inc.
Completed
NCT04733833 2023-02-01
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19
Vascular Biogenics Ltd. operating as VBL Therapeutics
Phase 2 Completed
NCT02107937 2022-05-04
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT03329690 2022-03-18
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Daiichi Sankyo
Phase 2 Completed
NCT02549222 2022-02-18
PIPER
Cerus Corporation
Completed
NCT04446429 2021-12-10
Anti-Androgen Treatment for COVID-19
Applied Biology, Inc.
Phase NA Completed
NCT01883362 2021-03-17
RADIUS
Novartis
Phase 2 Completed
NCT02039726 2021-02-24
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Daiichi Sankyo
Phase 3 Completed
NCT02369874 2021-02-10
EAGLE
AstraZeneca
Phase 3 Completed
NCT03255980 2020-12-16
Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®
Helsinn Healthcare SA
Phase NA Completed
NCT03323021 2020-11-13
Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy
MiMedx Group, Inc.
Phase NA Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT03472053 2020-05-19
A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer
BioMarck Pharmaceuticals, Ltd.
Phase 2 Completed
NCT03137264 2019-11-07
RADIANCE
AstraZeneca
Completed
NCT02200081 2018-11-15
IMPULSE
Mologen AG
Phase 2 Completed
NCT02107950 2018-08-15
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT02034799 2018-02-26
Phase IV Bioseal Study in Brain Tumor Surgery
Ethicon, Inc.
Phase 4 Completed
NCT01254318 2016-11-02
TRAFIC
Merck Sharp & Dohme LLC
Completed
NCT01360840 2015-12-14
PERSEUS
EMD Serono
Phase 2 Completed
NCT00355355 2015-01-30
A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
Light Sciences Oncology
Phase 3 Completed
NCT01129336 2014-05-20
MACS1295
Novartis
Phase 4 Completed
NCT00224068 2012-03-02
Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy
Watson Pharmaceuticals
Phase 4 Completed